单核/巨噬细胞在非霍奇金淋巴瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2020.04.011

摘要/Abstract

摘要： 非霍奇金淋巴瘤(Non-Hodgkin's lymphoma,NHL)是具有很强异质性的一组独立疾病的总称。近年来,人们发现在肿瘤微环境中,单核/巨噬细胞对肿瘤的生长、增殖、免疫逃逸及预后等都具有一定的影响,同时肿瘤也对单核/巨噬细胞产生刺激作用。本文对目前单核/巨噬细胞在几种常见NHL中的研究现状作简要综述,总结单核/巨噬细胞与NHL病人预后的相关性、单核/巨噬细胞与NHL肿瘤细胞的相互作用及机制,并对NHL的免疫疗法中单核/巨噬细胞可能扮演的作用进行阐述。

关键词: 非霍奇金淋巴瘤, 单核细胞, 巨噬细胞, 肿瘤相关巨噬细胞, 免疫疗法

Abstract: Non-Hodgkin's lymphoma(NHL)is a general term for a group of independent diseases with strong heterogeneity.In recent years,it's been found that in the tumor microenvironment,monocytes/macrophages have a certain effects on tumor growth,proliferation,immune escape and prognosis.At the same time,tumors also stimulate monocytes/macrophages.This article summarizes the current research status of monocytes/macrophages in several common NHL,summarizes the correlation between monocytes/macrophages and the prognosis of NHL patients,the interaction and mechanism of monocytes/macrophages and NHL tumor cells,and describes the possible role of monocytes/macrophages in immunotherapy of NHL.

Key words: Non-Hodgkin's lymphoma, Monocyte, Macrophage, Tumor-associated macrophages, Immuno-therapy

中图分类号:

R733.4

林映羲, 龙雅怡, 傅俊宏, 刘芳, 陈敏敏. 单核/巨噬细胞在非霍奇金淋巴瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 352-356.

LIN Yingxi, LONG Yayi, FU Junhong, LIU Fang, CHEN Minmin. Research progress of monocytes/macrophages in non-hodgkin's lymphomas[J]. Journal of Practical Oncology, 2020, 34(4): 352-356.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.04.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I4/352

参考文献

1 Zhou X,Pan H,Yang P,et al.Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma[J].BMC Cancer,2019,19(1):477.
2 Ansell SM.Non-hodgkin lymphoma:diagnosis and treatment[J].Mayo Clin Proc,2015,90(8):1152-1163.
3 Miranda-Filho A,Piñeros M,Znaor A,et al.Global patterns and trends in the incidence of non-hodgkin lymphoma[J].Cancer Causes Control,2019,30(5):489-499.
4 Yamaguchi M,Suzuki R,Oguchi M.Advances in the treatment of extranodal NK/T-cell lymphoma,nasal type[J].Blood,2018,131(23):2528-2540.
5 Brown JM,Recht L,Strober S.The promise of targeting macrophages in cancer therapy[J].Clin Cancer Res,2017,23(13):3241-3250.
6 Mantovani A,Marchesi F,Malesci A,et al.Tumour-associated macrophages as treatment targets in oncology[J].Nat Rev Clin Oncol,2017,14(7):399-416.
7 欧阳明祈.PD-1表达水平对非霍金淋巴瘤中肿瘤相关巨噬细胞功能影响的研究[D].北京:北京协和医学院,2018.
8 Wu C,Wu X,Liu X,et al.Prognostic significance of monocytes and monocytic myeloid-derived suppressor cells in diffuse large B-cell lymphoma treated with r-chop[J].Cell Physiol Biochem,2016,39(2):521-530.
9 George A,Prince HM,Szer J,et al.Prognostic impact of monocyte count at presentation in mantle cell lymphoma[J].Br J Haematol,2014,164(6):890-893.
10 Wang H,Li P,Wang L,et al.High numbers of CD68⁺ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma,nasal type[J].Ann Hematol,2015,94(9):1535-1544.
11 Kato A,Imai Y,Aoki K,et al.Serum IgA level,monocyte count,and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma[J].Ann Hematol,2014,93(7):1185-1191.
12 Yang YQ,Liang JH,Wu JZ,et al.Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma[J].Leuk Res,2016,42:88-92.
13 Lee SF,Luque-Fernandez MA.Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma:a retrospective cohort study[J].BMJ Open,2017,7(11):e017904.
14 Li N,Zhang L,Song HL,et al.Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type,extranodal natural killer/T-cell lymphoma[J].Tumour Biol,2017,(39)5:1-11.
15 Li Q,Gao S,Ma J,et al.A lower ALC/AMC ratio is associated with poor prognosis of peripheral T cell lymphoma-not otherwise specified[J].Leuk Res,2018,73:5-11.
16 Jia T,Zhang R,Zhu HY,et al.Prognostic significance of peripheral blood absolute monocyte count and lymphocyte to monocyte ratio in anaplastic large cell lymphoma[J].Cancer Biomark,2018,22(4):807-813.
17 Matsuki E,Bohn OL,EI Jamal S,et al.Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab[J].Appl Immunohistochem Mol Morphol,2019,27(8):572-580.
18 Sugimoto T,Watanabe T.Follicular lymphoma:the role of the tumor microenvironment in prognosis[J].J Clin Exp Hematop,2016,56(1):1-19.
19 Lin ZX,Bai B,Cai QC,et al.High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T-and natural killer cell lymphomas[J].Med Oncol,2012,29(5):3522-3528.
20 Liu Y,Fan L,Wang Y,et al.Tumor-associated macrophages promote tumor cell proliferation in nasopharyngeal NK/T-cell lymphoma[J].Int J Clin Exp Pathol,2014,7(9):5429-5435.
21 Ham JS,Park HY,Ryu KJ,et al.Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma[J].Oncotarget,2017,8(44):76231-76240.
22 Niino D,Komohara Y,Murayama T,et al.Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma(AITL)[J].PatholInt,2010,60(4):278-283.
23 Pedersen MB,Danielsen AV,Hamilton-Dutoit SJ,et al.High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma[J].Histopathology,2014,65(4):490-500.
24 Komohara Y,Niino D,Saito Y,et al.Clinical significance of CD163⁺ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma[J].Cancer Sci,2013,104(7):945-951.
25 Sugaya M,Miyagaki T,Ohmatsu H,et al.Association of the numbers of CD163⁺ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma[J].J Dermatol Sci,2012,68(1):45-51.
26 Zhang W,Wang L,Zhou D,et al.Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma,not otherwise specified[J].Leuk Lymphoma,2011,52(1):46-52.
27 Noyori O,Komohara Y,Nasser H,et al.Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma[J].Clin Transl Immunology,2019,8(8):e1074.
28 Ishii H,Takahara M,Nagato T,et al.Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact dependent interaction through membrane-bound IL-15[J].Int J Cancer,2012,130(1):48-58.
29 Xiu B,Lin Y,Grote DM,et al.IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-)monocytes in B-cell non-Hodgkin lymphoma[J].Blood Cancer J,2015,31:e328.
30 Voss JJLP,Ford CA,Petrova S,et al.Modulation of macrophage antitumor potential by apoptotic lymphoma cells[J].Cell Death Differ,2017,24(6):971-983.
31 Mendoza-Coronel E,Ortega E.Macrophage polarization modulates FcgR-and CD13-mediated phagocytosis and reactive oxygen species production,independently of receptor membrane expression[J].Front Immunol,2017,8:303.
32 Chaudhari P,Ye Z,Jang YY.Roles of reactive oxygen species in the fate of stem cells[J].Antioxid Redox Signal,2014,20(12):1881-1890.
33 Lin YM,Huang YL,Fong YC,et al.Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-met receptor pathway[J].PLoS One,2012,7(11):e50924.
34 Huang W,Wei X,Wei Y,et al.Biology of tumor associated macrophages in diffuse large B cell lymphoma[J].DNA Cell Biol,2018[Online ahead of print].
35 Vari F,Arpon D,Keane C,et al.Immune evasion via PD-1/PD-L1 on NK-Cells and monocyte/macrophages is more prominent in hodgkin lymphoma than DLBCL[J].Blood,2018,131(16):1809-1819.
36 McKee SJ,Tuong ZK,Kobayashi T,et al.B cell lymphoma progression promotes the accumulation of circulating Ly6C^lo monocytes with immunosuppressive activity[J].Oncoimmunology,2017,7(2):e1393599.
37 Church AK,VanDerMeid KR,Baig NA,et al.Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages[J].Clin Exp Immunol,2016,183(1):90-101.
38 Sawas A,Farber CM,Schreeder MT,et al.A phase 1/2 trial of ublituximab,a novel anti-CD20 monoclonal antibody,in patients with B-cell non-hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab[J].Br J Haematol,2017,177(2):243-253.
39 Chao MP,Alizadeh AA,Tang C,et al.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma[J].Cell,2010,142(5):699-713.
40 Advani R,Flinn I,Popplewell L,et al.CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma[J].N Engl J Med,2018,379(18):1711-1721.
41 He J,Hu Y,Hu M,et al.Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J].Sci Rep,2015,5:13110.
42 Kwong YL,Chan TSY,Tan D,et al.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase[J].Blood,2017,129(17):2437-2442.
43 Lesokhin AM,Ansell SM,Armand P,et al.Nivolumab in patients with relapsed or refractory hematologic malignancy:preliminary results of a phase ib study[J].J Clin Oncol,2016,34(23):2698-2704.
44 Priceman SJ,Sung JL,Shaposhnik Z,et al.Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1receptor:combating tumor evasion of antiangiogenic therapy[J].Blood,2010,115(7):1461-1471.

[1]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[2]	张培, 曹守波, 于雁. 自噬介导的肿瘤相关巨噬细胞调控机制的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 130-134.
[3]	唐蒙蒙, 刘天伯, 王晶审校. LMR与妇科恶性肿瘤预后的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 569-572.
[4]	张爱岐, 金时, 曹守波(综述), 于雁(审校). 淋巴细胞/单核细胞比值对恶性肿瘤患者预后评估的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 188-192.
[5]	余长艳, 甄丽娜, 李洪滨, 张悦, 张清媛. 肿瘤相关巨噬细胞在三阴性乳腺癌中的表达与临床病理因素及预后关系的研究[J]. 实用肿瘤学杂志, 2017, 31(1): 1-6.
[6]	牟冠男, 李琦, 赵娟, 吴杨佳子, 王东亮, 李殿俊, 张艳桥, 黄小义. 不同细胞因子对DC成熟的影响及细胞穿膜肽的穿膜效率比较[J]. 实用肿瘤学杂志, 2016, 30(3): 207-213.
[7]	甄丽娜,余长艳,李洪滨(综述),张悦,张清媛(审校). 腋结阴性乳腺癌复发转移相关因素及其对治疗决策影响的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 183-187.
[8]	宋庆华,尚辉,曾令洲,许安荣,赵望明,李玉斌. 右肱骨干骨原发性非霍奇金淋巴瘤1例报告[J]. 实用肿瘤学杂志, 2014, 28(5): 442-444.
[9]	张, 悦, 张清媛, 马文杰, 甄丽娜. 肿瘤相关巨噬细胞的过表达示腋下淋巴结阴性乳腺癌预后不良[J]. 实用肿瘤学杂志, 2013, 27(4): 289-294.
[10]	陆颖, 黄海欣, 李桂生. GEMOX方案治疗复发或难治性非霍奇金淋巴瘤[J]. 实用肿瘤学杂志, 2011, 25(6): 547-550.
[11]	付冬伟综述, 吴, 瑾审校. MIC-1在相关肿瘤中的表达及意义[J]. 实用肿瘤学杂志, 2008, 22(6): 575-577.
[12]	韩立春;郝彦勇;郭海燕. 非霍奇金淋巴瘤中PTEN和PCNA表达的临床、病理关系研究[J]. 实用肿瘤学杂志, 2007, 21(04): 319-321.
[13]	张瑞丽;张景萍;张静;李新华;张开明. NHL患者血清TNF-α、LDH水平及与血沉的相关性研究[J]. 实用肿瘤学杂志, 2006, 20(01): 9-11.
[14]	鲍慧铮;程颖;丛琦. FMD/R-FMD方案治疗老年复发NHL 17例报告[J]. 实用肿瘤学杂志, 2005, 19(04): 249-251.
[15]	吴宏菊;张清媛;康欣梅;孙理;关小军;陈德发;马军. IMVP-16方案治疗复发和难治性非霍奇金淋巴瘤的临床观察[J]. 实用肿瘤学杂志, 2004, 18(06): 447-448.